Crestline Management LP acquired a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 50,957 shares of the company’s stock, valued at approximately $2,584,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parallel Advisors LLC grew its stake in shares of Ionis Pharmaceuticals by 62.8% during the 2nd quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after purchasing an additional 800 shares during the period. Hanseatic Management Services Inc. grew its stake in shares of Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after purchasing an additional 41 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after purchasing an additional 311 shares during the period. WFG Advisors LP grew its stake in shares of Ionis Pharmaceuticals by 77.2% during the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after purchasing an additional 1,655 shares during the period. Finally, CIBC Asset Management Inc acquired a new stake in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $212,000. 91.59% of the stock is currently owned by institutional investors and hedge funds.

Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) opened at $54.60 on Monday. Ionis Pharmaceuticals, Inc. has a one year low of $37.26 and a one year high of $65.51. The stock has a market cap of $6,790.00, a price-to-earnings ratio of 364.00 and a beta of 2.85. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50.

A number of brokerages have recently commented on IONS. BidaskClub raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday. Zacks Investment Research cut shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. BMO Capital Markets raised their price objective on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 8th. Morgan Stanley raised their price objective on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 8th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $50.31.

In related news, SVP Elizabeth L. Hougen sold 4,000 shares of Ionis Pharmaceuticals stock in a transaction on Monday, December 4th. The shares were sold at an average price of $57.00, for a total value of $228,000.00. Following the sale, the senior vice president now owns 14,392 shares of the company’s stock, valued at approximately $820,344. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stanley T. Crooke sold 15,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $52.00, for a total value of $780,000.00. Following the completion of the transaction, the chief executive officer now owns 43,014 shares in the company, valued at approximately $2,236,728. The disclosure for this sale can be found here. Insiders sold a total of 123,886 shares of company stock worth $7,098,315 in the last three months. 2.13% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/12/11/crestline-management-lp-invests-2-58-million-in-ionis-pharmaceuticals-inc-ions.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.